Kyongbo Pharmaceutical
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Kyongbo Pharmaceutical makes active pharmaceutical ingredients, the raw chemical compounds that go into finished medicines, as well as finished prescription and over-the-counter drugs, with cephalosporin antibiotics (a widely used antibiotic family) among its best-known products.
It supplies domestic drug makers and hospitals, and also exports its active ingredients to markets in developed countries. Listed on KOSPI, Korea's main stock exchange, the company operates two roughly equal revenue streams: bulk active ingredients and finished dosage-form medicines, complemented by smaller medical-device and animal-health businesses.
Summary is AI-generated and may contain errors · figures from DART filings
The company is developing its own conjugation and payload-linker technologies to enter the global contract development and manufacturing market for antibody-drug conjugate cancer therapies.
Kyongbo Pharmaceutical in five facts
What does Kyongbo Pharmaceutical do?
Kyongbo Pharmaceutical makes active pharmaceutical ingredients, the raw chemical compounds that go into finished medicines, as well as finished prescription and over-the-counter drugs, with cephalosporin antibiotics (a widely used antibiotic family) among its best-known products.
Where is Kyongbo Pharmaceutical listed and in which sector?
Kyongbo Pharmaceutical (Korean name: 경보제약) trades under KRX code 214390 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Pharmaceuticals.
How large is Kyongbo Pharmaceutical?
Its market capitalisation was US$96.2M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Kyongbo Pharmaceutical's latest annual revenue and operating profit?
For fiscal year 2025, Kyongbo Pharmaceutical reported revenue of US$199.3M, operating profit of US$2.7M and net income of US$137.6K, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 10.7% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Amended] Material event report (business suspension)Sep 30
- [Amended] Material event report (business suspension)Aug 31
- Operating results (preliminary) (fair disclosure)
Kyongbo Pharmaceutical filed provisional (unaudited) separate results for Q2 2026: revenue of US$53M (+15.2% year on year), operating profit of US$655K (−61.4% year on year) and net income of US$2.09M (from a loss a year earlier).
Earnings · Jul 31 - Operating results (preliminary) (fair disclosure)
Kyongbo Pharmaceutical filed provisional (unaudited) separate results for Q1 2026: revenue of US$44.5M (+9.1% year on year), operating profit of US$479K (+489.3% year on year) and a net loss of US$356K.
Earnings · Apr 29 - Supply contract terminatedSupply contract · Apr 10
- Cash/in-kind dividend decision
Kyongbo Pharmaceutical declared a cash dividend of US$0.03 per share.
Dividend · Feb 24 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)Earnings · Feb 2